Subscribe to RSS
DOI: 10.1055/s-0043-1775462
Design, Synthesis, and Molecular Docking Studies of Sulfonyl-Substituted Chromene Derivatives as Anticancer Agents
Abstract
This study explores the role of estrogen in breast cancer development through ERα and ERβ receptors and highlights the significance of aromatase in estrogen biosynthesis. Chromene-based compounds, known for their anticancer properties, were synthesized with sulfonyl substitutions to enhance their efficacy. The MTT assay on MCF-7, MDA-MB-231, and HCT-116 cancer cell lines showed that (Z)-N-(3-cyano-2H-chromen-2-ylidene)benzenesulfonamide (AN1) and (Z)-N-(6-bromo-3-cyano-2H-chromen-2-ylidene)methanesulfonamide (AN13) had strong cytotoxic activity. Aromatase inhibitory assay shows that compound AN1 and AN13 show good inhibitory activity with IC50 values 0.20 and 0.24 μM. Docking studies revealed that these compounds fit well at the active site of the aromatase enzyme, with AN1, AN2, AN3, AN7, AN8, and AN13 showing docking scores of –9.1, –9.0, –8.8, –8.0, –8.6, and –7.8, respectively, compared to Exemestane with –9.3. ADME predictions indicated good drug-like properties, suggesting that these chromene derivatives could be effective anticancer agents.
Supporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/s-0043-1775462.
- Supporting Information
Publication History
Received: 26 December 2024
Accepted after revision: 27 February 2025
Article published online:
04 April 2025
© 2025. Thieme. All rights reserved
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Matthews HK, Bertoli C, de Bruin RA. Nat. Rev. Mol. Cell Biol. 2022; 23: 74
- 2 Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Mol Cancer Res. 2023; 21: 1142
- 3 Liu J, Erenpreisa J, Sikora E. Semin. Cancer Biol. 2022; 81: 1
- 4 Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. J. Hepatol. 2022; 77: 1598
- 5 Liu L, Villavicencio F, Yeung D, Perin J, Lopez G, Strong KL, Black RE. Lancet Global Health 2022; 10: e337
- 6 Byrne S, Boyle T, Ahmed M, Lee SH, Benyamin B, Hyppönen E. Int. J. Epidemiol. 2023; 52: 817
- 7 Retracted paper (see retraction notice for full details): Kashyap D, Pal D, Sharma R, Garg VK, Goel N, Koundal D, Zaguia A, Koundal S, Belay A. BioMed Res. Int. 2022; 2022 01: 9605439
- 8 Pai HD, Samuel SR, Kumar KV, Eapen C, Olsen A, Keogh JW. PeerJ 2024; 12: e17107
- 9 Yan C, Shan F, Ying X, Li Z. Chin. Med. J. 2023; 136: 397
- 10 Sankarapillai J, Krishnan S, Ramamoorthy T, Sudarshan KL, Das P, Chaturvedi M, Mathur P. J. Public Health. 2023; 223: 230
- 11 Nakata K, Gatellier L. Jpn. J. Clin. Oncol. 2022; 52: 288
- 12 Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Indian J. Med. Res. 2022; 156: 598
- 13 Miziak P, Baran M, Błaszczak E, Przybyszewska-Podstawka A, Kałafut J, Smok-Kalwat J, Dmoszyńska-Graniczka M, Kiełbus M, Stepulak A. Cancers (Basel) 2023; 15: 4689
- 14 Kumar R. Vitam. Horm. 2023; 123: 399
- 15 Erzurumlu Y, Doğan HK. J. Interdiscip. Med. 2023; 14: 57
- 16 Rawłuszko-Wieczorek AA, Romanowska K, Nowicki M. Biomed. Pharmacother. 2022; 153: 113548
- 17 Ghosh D. Steroids 2023; 196: 109249
- 18 Alwan M, Afzaljavan F. Arch Razi Inst. 2022; 77: 943
- 19 Mahapatra M, Mohapatra P, Sahoo SK, Bishoyi AK, Padhy RN, Paidesetty SK. J. Mol. Struct. 2023; 1283: 135190
- 20 Ivanova L, Karelson M. Molecules 2022; 27: 9041
- 21 Yang C, Chen EA, Zhang Y. Molecules 2022; 27: 4568